207 related articles for article (PubMed ID: 38629624)
21. Malignant pleural effusion as a predictor of the efficacy of anti-PD-1 antibody in patients with non-small cell lung cancer.
Shibaki R; Murakami S; Shinno Y; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Motoi N; Yamamoto N; Ohe Y
Thorac Cancer; 2019 Apr; 10(4):815-822. PubMed ID: 30762312
[TBL] [Abstract][Full Text] [Related]
22. Osteopontin is involved in the formation of malignant pleural effusion in lung cancer.
Cui R; Takahashi F; Ohashi R; Yoshioka M; Gu T; Tajima K; Unnoura T; Iwakami S; Hirama M; Ishiwata T; Iwase A; Takahashi K
Lung Cancer; 2009 Mar; 63(3):368-74. PubMed ID: 18752867
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of osimertinib in patients with EGFR-mutation positive non-small cell lung cancer with malignant pleural effusion.
Kiritani A; Amino Y; Uchibori K; Akita T; Harutani Y; Ogusu S; Tsugitomi R; Manabe R; Ariyasu R; Kitazono S; Yanagitani N; Nishio M
Thorac Cancer; 2024 Feb; 15(5):402-409. PubMed ID: 38226415
[TBL] [Abstract][Full Text] [Related]
24. Extracellular Vesicle MicroRNA in Malignant Pleural Effusion.
Shojaee S; Romano G; Sanchez TM; Yermakhanova G; Saviana M; Le P; Nigita G; Calore F; Guthrie R; Hess K; Kang L; Swift-Scanlan T; Graham JT; Rahman NM; Nana-Sinkam PS; Acunzo M
Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36421832
[TBL] [Abstract][Full Text] [Related]
25. Downregulation of miR-4772-3p promotes enhanced regulatory T cell capacity in malignant pleural effusion by elevating Helios levels.
Yu WQ; Ji NF; Gu CJ; Sun ZX; Wang ZX; Chen ZQ; Ma Y; Wu ZZ; Wang YL; Wu CJ; Ding MD; Dai GH; Yao J; Jin RR; Huang M; Zhang MS
Chin Med J (Engl); 2019 Nov; 132(22):2705-2715. PubMed ID: 31725455
[TBL] [Abstract][Full Text] [Related]
26. The diagnostic value of apolipoprotein E in malignant pleural effusion associated with non-small cell lung cancer.
Wang Y; Chen Z; Chen J; Pan J; Zhang W; Pan Q; Ding H; Lin X; Wen X; Li Y; Meng QH
Clin Chim Acta; 2013 Jun; 421():230-5. PubMed ID: 23523589
[TBL] [Abstract][Full Text] [Related]
27. Clinical value of combined detection of reactive oxygen species modulator 1 and adenosine deaminase in pleural effusion in the identification of NSCLC associated malignant pleural effusion.
Zhang F; Wang J; Fu J; Hu L; Zheng X; Wang Y; Chen B
J Clin Lab Anal; 2020 Mar; 34(3):e23091. PubMed ID: 31709646
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic value of pleural effusion Krebs von den Lungen-6 in malignant pleural effusion of patients with non-small cell lung cancer.
Wang J; Ling L; Chen S; Chou L; Wang Y; Hu L
Lab Med; 2024 May; 55(3):271-276. PubMed ID: 37566516
[TBL] [Abstract][Full Text] [Related]
29. Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer‑mediated malignant pleural effusion.
Du N; Li X; Li F; Zhao H; Fan Z; Ma J; Fu Y; Kang H
Oncol Rep; 2013 Jun; 29(6):2332-40. PubMed ID: 23525453
[TBL] [Abstract][Full Text] [Related]
30. A Multicancer Malignant Pleural Effusion Diagnostic Test Using Hexokinase 2 and Single-Cell Sequencing.
Chen J; Yang Y; Wang Z; Shen X; Zhang Z; Wang C; Xu H; Shi Q
Clin Chem; 2022 May; 68(5):680-690. PubMed ID: 35142335
[TBL] [Abstract][Full Text] [Related]
31. Culture and multiomic analysis of lung cancer patient-derived pleural effusions revealed distinct druggable molecular types.
Seo HY; Kim SC; Roh WL; Shin YK; Kim S; Kim DW; Kim TM; Ku JL
Sci Rep; 2022 Apr; 12(1):6345. PubMed ID: 35428753
[TBL] [Abstract][Full Text] [Related]
32. Identification of Potential Biomarkers of EGFR Mutation in Pleural Effusion of Non-Small Cell Lung Cancer Patients Based on Metabolomics.
Yu J; Xu H; Feng T; Xie T; Shi T
Clin Lab; 2024 Jun; 70(6):. PubMed ID: 38868885
[TBL] [Abstract][Full Text] [Related]
33. mRNA markers associated with malignant pleural effusion.
Hsu SC; Chang SY; Hwang YT; Terng HJ; Tsai CL; Shen CH; Huang SK; Chian CF
Sci Rep; 2023 Apr; 13(1):6677. PubMed ID: 37095178
[TBL] [Abstract][Full Text] [Related]
34. Single-cell analysis of diverse immune phenotypes in malignant pleural effusion.
Huang ZY; Shao MM; Zhang JC; Yi FS; Du J; Zhou Q; Wu FY; Li S; Li W; Huang XZ; Zhai K; Shi HZ
Nat Commun; 2021 Nov; 12(1):6690. PubMed ID: 34795282
[TBL] [Abstract][Full Text] [Related]
35. Surgical intervention for non-small-cell lung cancer with minimal malignant pleural effusion.
Iwasaki M; Shimomura M; Ishihara S; Yamaguchi T; Kishimoto M; Ii T; Inoue M
Surg Today; 2023 Jun; 53(6):655-662. PubMed ID: 36310332
[TBL] [Abstract][Full Text] [Related]
36. WIF-1 promoter region hypermethylation as an adjuvant diagnostic marker for non-small cell lung cancer-related malignant pleural effusions.
Yang TM; Leu SW; Li JM; Hung MS; Lin CH; Lin YC; Huang TJ; Tsai YH; Yang CT
J Cancer Res Clin Oncol; 2009 Jul; 135(7):919-24. PubMed ID: 19085002
[TBL] [Abstract][Full Text] [Related]
37. Detecting EGFR mutations and ALK/ROS1 rearrangements in non-small cell lung cancer using malignant pleural effusion samples.
Yao Y; Peng M; Shen Q; Hu Q; Gong H; Li Q; Zheng Z; Xu B; Li Y; Dong Y
Thorac Cancer; 2019 Feb; 10(2):193-202. PubMed ID: 30565433
[TBL] [Abstract][Full Text] [Related]
38. Clinical course of asymptomatic malignant pleural effusion in non-small cell lung cancer patients: A multicenter retrospective study.
Roh J; Ahn HY; Kim I; Son JH; Seol HY; Kim MH; Lee MK; Eom JS
Medicine (Baltimore); 2021 May; 100(19):e25748. PubMed ID: 34106603
[TBL] [Abstract][Full Text] [Related]
39. S100A2: A potential biomarker to differentiate malignant from tuberculous pleural effusion.
Wang T; Wang N; Zhang L; Liu Y; Thakur A
Indian J Cancer; 2021; 58(2):241-247. PubMed ID: 33402562
[TBL] [Abstract][Full Text] [Related]
40. Novel insights into the systemic treatment of lung cancer malignant pleural effusion.
Tissot C; Gay P; Brun C; Froudarakis ME
Clin Respir J; 2019 Mar; 13(3):131-138. PubMed ID: 30737898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
